Actinium Pharmaceuticals awarded director Steinhart Richard I 62,800 shares at $0 per share on September 2, 2026. For investors, the transaction records 63,116 shares owned afterward and a separate 94,200 derivative securities position, giving the ownership update both Equity and derivative components.
Key Highlights
- Steinhart Richard I owned 63,116 Actinium Pharmaceuticals shares after the transaction.
- The director’s post-transaction derivative securities holding was 94,200.
- Steinhart Richard I was awarded 62,800 Actinium Pharmaceuticals shares on September 2, 2026.
Actinium Pharmaceuticals, Inc. (AMEX: ATNM) awarded Steinhart Richard I 62,800 shares at $0 per share on September 2, 2026. The filing also reports an award of 94,200 derivative securities to Steinhart Richard I on the same date.
Director’s Post-Transaction Holdings
Steinhart Richard I owned 63,116 Actinium Pharmaceuticals shares after the award. The post-transaction derivative securities balance was also 94,200. The records identify Steinhart Richard I as a director of Actinium Pharmaceuticals.
FAQs
Q: How many Actinium Pharmaceuticals shares did Steinhart Richard I receive?
A: Actinium Pharmaceuticals awarded Steinhart Richard I 62,800 shares at $0 per share on September 2, 2026. He owned 63,116 shares after the transaction.
Q: What derivative securities does the Actinium Pharmaceuticals director hold?
A: The filing states that Steinhart Richard I was awarded 94,200 derivative securities of Actinium Pharmaceuticals on September 2, 2026, under transaction code A. Following the transaction, he owned 94,200 derivative securities.
Q: What was the price of the Actinium Pharmaceuticals share award?
A: The 62,800-share award to Steinhart Richard I was recorded at $0 per share. The transaction date was September 2, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.